Assess
Independent evaluation of pharmaceutical compliance risk
Leadership sometimes needs an assessment that is separate from the team designing or executing the corrective work.
Tailwind evaluates the facts, evidence, quality-system performance, management oversight, and likely points of regulatory scrutiny so decision-makers can act from a defensible view of risk.
FDA inspection announced — or investigators already on site?
Get inspection help nowThe question is not simply whether a procedure exists. The question is whether the system works, whether management knows when it does not work, and whether the evidence supports the decisions being made.
What the engagement includes
- Risk-based review of quality systems, inspection history, and open commitments
- Independent challenge of investigations, CAPAs, and effectiveness evidence
- Assessment of management oversight and escalation practices
- Prioritized findings with practical decision points
- Executive briefing suitable for leadership, boards, counsel, or investors
- Clear boundaries between confirmed facts, assumptions, and residual risk
When teams call
- Management needs a credible view beyond internal status reporting
- A transaction depends on understanding GMP or enforcement exposure
- Several remediation workstreams need independent prioritization
- Counsel needs technical assessment of a manufacturing compliance matter
- A contract manufacturer's performance presents supply and quality risk
How we approach it
Start with evidence
The assessment separates documented performance from planned activity, unsupported conclusions, and assumptions that still need testing.
Evaluate regulatory significance
Findings are considered in context: product impact, recurrence, inspection history, management awareness, and the effectiveness of current controls.
Give leaders decisions
The output is designed to support priorities, escalation, investment, and governance—not simply create another list of gaps.
Related services
Common questions on timelines, scope, and cost are answered on the FAQ page, and engagement terms are on pricing.
Tailwind Pharma provides independent advisory services and does not replace the manufacturer's designated Quality Unit or guarantee regulatory outcomes.